SEC Form 4 · accession 0001493152-17-000150
Adhera Therapeutics, Inc. · ATRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph W. Ramelli
Officer — Chief Executive Officer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000737207
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $0.17 | Jan 3, 2017 | A | 81,000 | A | — | Jan 3, 2022 | common stock | 81,000 | 81,000 | D |
Explanation of responses
- F1Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018.